Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hypersensitivity Reaction
  Free Subscription

Articles published in
J Am Acad Dermatol
    March 2026
  1. HAGINO T, Saeki H, Fujimoto E, Kanda N, et al
    Response to lebrikizumab in atopic dermatitis patients who failed upadacitinib: 48-week real-world outcomes.
    J Am Acad Dermatol. 2026 Mar 24:S0190-9622(26)00465.
    >> Share

  2. EZZAT RZ, Paz M, Chen LC, Sharma D, et al
    Infections and Hospitalizations in Adolescents with Atopic Dermatitis Treated with Oral Janus Kinase Inhibitors: A Cohort Study Using TriNetX.
    J Am Acad Dermatol. 2026 Mar 13:S0190-9622(26)00400.
    >> Share

  3. HAGINO T, Saeki H, Fujimoto E, Kanda N, et al
    A 144-week real-world outcomes of upadacitinib 30 mg for atopic dermatitis in poor responders to 15 mg.
    J Am Acad Dermatol. 2026 Mar 2:S0190-9622(26)00326.
    >> Share

  4. MODANLO N, Cheng K, Nguyen MO, Truong A, et al
    Biologic therapies for dermatologic emergencies: A comprehensive review.
    J Am Acad Dermatol. 2026;94:895-902.
    >> Share

    February 2026
  5. CHAN KR, Keddie SH, Flohr C, Tsoi MF, et al
    Correction to Prevalence of atopic dermatitis in the United States from 2021 to 2024: Data from the National Health Interview Survey [Journal of the American Academy of Dermatology 2026 Feb;94(2)633-635].
    J Am Acad Dermatol. 2026 Feb 24:S0190-9622(26)00305.
    >> Share

  6. ARMSTRONG AW, Gooderham MJ, Eyerich K, Reich K, et al
    Onset and depth of response with abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis, including prominent head-and-neck dermatitis: A post hoc analysis of the head-to-head phase 3 JADE DARE study.
    J Am Acad Dermatol. 2026 Feb 20:S0190-9622(26)00284.
    >> Share

  7. FAN YH, Fan KS, Lin TL
    Comparative Hazards of Ocular Surface Disorders with IL-4/13 versus IL-13 Inhibitors in Atopic Dermatitis: A TriNetX Database Study.
    J Am Acad Dermatol. 2026 Feb 19:S0190-9622(26)00270.
    >> Share

  8. SILVERBERG JI, Eichenfield LF, Armstrong AW, Bagel J, et al
    The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial.
    J Am Acad Dermatol. 2026 Feb 16:S0190-9622(26)00230.
    >> Share

  9. CERAVALLS J, Figueras-Nart I, Julia Manresa M, Prados-Carmona A, et al
    Upadacitinib dose increase to 45 mg daily for refractory atopic dermatitis.
    J Am Acad Dermatol. 2026 Feb 13:S0190-9622(26)00229.
    >> Share

  10. YANG K, Wen X, Chen X
    Dupilumab, Atopic Dermatitis, and Linear Growth: Navigating Beyond Association to Mechanism and Intervention.
    J Am Acad Dermatol. 2026 Feb 11:S0190-9622(26)00187.
    >> Share

  11. CHEN TL, Ma SH, Ou WF, Chen CC, et al
    Response to Chen et al., "Dupilumab, Atopic Dermatitis, and Linear Growth: Navigating Beyond Association to Mechanism and Intervention.".
    J Am Acad Dermatol. 2026 Feb 11:S0190-9622(26)00186.
    >> Share

  12. ZHANG H, You S
    Letter to "Effect of prenatal high-dose vitamin D on childhood atopic dermatitis is modified by maternal cotinine metabolome: A secondary analysis of a randomized clinical trial".
    J Am Acad Dermatol. 2026 Feb 9:S0190-9622(26)00175.
    >> Share

  13. KONDOR L, Cicala G, Salvo F, Clabecq C, et al
    Drugs associated with generalized non-allergic pruritus: A World Health Organization pharmacovigilance database analysis.
    J Am Acad Dermatol. 2026 Feb 7:S0190-9622(26)00176.
    >> Share

  14. VERONESE F, Teresa Boggio CM, Armari M, Airoldi C, et al
    Therapy-Dependent Modulation of Staphylococcus aureus Colonization in Atopic Dermatitis: Insights from Anti-IL-4/IL-13 and JAK Inhibition.
    J Am Acad Dermatol. 2026 Feb 3:S0190-9622(26)00102.
    >> Share

  15. LUTZ W, Hua C, Mariotti EB, Terrier B, et al
    Risk factors for recurrence or relapse after a first episode of adult IgA vasculitis: A multicenter retrospective study.
    J Am Acad Dermatol. 2026;94:495-502.
    >> Share

    December 2025
  16. KARELS S, Weber B, Lee K
    Allergenicity of Dollar Store Personal Care Products: Financial Implications for Patients with Allergic Contact Dermatitis.
    J Am Acad Dermatol. 2025 Dec 31:S0190-9622(25)03498.
    >> Share

  17. QIU Y, Ding Y, Hu W, Wang H, et al
    Long-Term Dupilumab Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis: A Real-World Single-Center Retrospective Study.
    J Am Acad Dermatol. 2025 Dec 30:S0190-9622(25)03488.
    >> Share

  18. SIMPSON EL, Schuttelaar MA, Molin S, Goncalo M, et al
    Dupilumab treatment improves health-related quality of life in patients with moderate-to-severe atopic dermatitis primarily affecting the hands (atopic hand eczema): results from a randomized placebo-controlled trial.
    J Am Acad Dermatol. 2025 Dec 26:S0190-9622(25)03460.
    >> Share

  19. HU J, Ma J, Wang Y, Tang F, et al
    The Mediating Role of Asthma in the Association Between Atopic Dermatitis and ADHD: A Population-Based Study in Children and Adolescents Using the NHANES Database.
    J Am Acad Dermatol. 2025 Dec 23:S0190-9622(25)03449.
    >> Share

  20. KARELS S, Weber B, Hylwa S
    High Discrepancy Rates in Online Allergen Platforms: Implications for Allergen Avoidance.
    J Am Acad Dermatol. 2025 Dec 23:S0190-9622(25)03447.
    >> Share

  21. BALAN K, Lallas A, Akdogan N
    Patterns and Pitfalls: Dermoscopic Differentiation of Early-Stage Mycosis Fungoides, Atopic Dermatitis, and Psoriasis.
    J Am Acad Dermatol. 2025 Dec 17:S0190-9622(25)03431.
    >> Share

  22. HAWRYLUK E, Murase JE, Frazer-Green L
    Response to Davis et al, "Focused update: Guidelines of care for the management of atopic dermatitis in adults".
    J Am Acad Dermatol. 2025 Dec 13:S0190-9622(25)03295.
    >> Share

  23. TSAI YA
    Comment on "Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network" by Katherine Benandi et al.
    J Am Acad Dermatol. 2025 Dec 11:S0190-9622(25)03365.
    >> Share

  24. BOETES J, Zemlok SK, Polen K, Dharmesh E, et al
    Dupilumab Response in Children and Adolescents With Atopic Dermatitis Across Racial and Ethnic Groups: A Retrospective Cohort Study.
    J Am Acad Dermatol. 2025 Dec 3:S0190-9622(25)03313.
    >> Share

    November 2025
  25. DAI Y, Wang Y, Luo H, Tan J, et al
    Association Between Endometriosis and Atopic Dermatitis: Evidence from NHANES and Genetic Causal Inference.
    J Am Acad Dermatol. 2025 Nov 27:S0190-9622(25)03285.
    >> Share

  26. HERRERA HO, Bordeaux JS
    Risk of Pediatric Infections Following Dupilumab Treatment for Atopic Dermatitis: A TriNetX Cohort Study.
    J Am Acad Dermatol. 2025 Nov 15:S0190-9622(25)03229.
    >> Share

  27. YOSIPOVITCH G, Zirwas M, Rasouliyan L, Althoff AG, et al
    Combined Impact of Lesion and Itch Severity on Initiation of Biologic Treatment in Patients with Moderate or Severe Atopic Dermatitis from Specialty Dermatology Facilities in the United States.
    J Am Acad Dermatol. 2025 Nov 12:S0190-9622(25)03187.
    >> Share

  28. SOOD S, Bagit A, Maliyar K, Georgakopoulos JR, et al
    Five-year real-world drug survival of dupilumab in patients with atopic dermatitis: A multicenter retrospective study.
    J Am Acad Dermatol. 2025 Nov 7:S0190-9622(25)03150.
    >> Share

  29. BISSONNETTE R, Agner T, Molin S, Guttman-Yassky E, et al
    Hand eczema-Part 1: Epidemiology, pathogenesis, diagnosis, and work-up.
    J Am Acad Dermatol. 2025;93:1201-1210.
    >> Share

    October 2025
  30. FISHER C, Wohltmann WE
    JAAD Game Changers: "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study".
    J Am Acad Dermatol. 2025 Oct 29:S0190-9622(25)03101.
    >> Share

  31. DULAI AS, Murase EM, Avallone G, Ferrucci SM, et al
    International Multi-Center Case Series of Gestational Dupilumab Exposure in the Treatment of Atopic Dermatitis: Maternal Complications and Fetal Outcomes.
    J Am Acad Dermatol. 2025 Oct 29:S0190-9622(25)03123.
    >> Share

  32. SEIFERT RM, Teames CR, Sahni V, Noot C, et al
    The Impact of Allergen Avoidance on Oral Lichen Planus:A Retrospective Cohort-Based Comparison.
    J Am Acad Dermatol. 2025 Oct 13:S0190-9622(25)03008.
    >> Share

  33. SCHNEEWEISS MC, Glynn RJ, Anand P, Jin Y, et al
    Choice of new treatment for patients with atopic dermatitis is associated with insurance status rather than race: A cross sectional study from commercial and Medicaid insurance claims databases.
    J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02969.
    >> Share

  34. KANG HE, Lee A, Wang SP, Ye M, et al
    Examining the Impact of Child Atopic Dermatitis on Maternal Depression: A Longitudinal Cohort Study.
    J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02968.
    >> Share

  35. CHAN KR, Keddie SH, Flohr C, Tsoi MF, et al
    Prevalence of atopic dermatitis in the United States from 2021-2024: data from the National Health Interview Survey.
    J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02973.
    >> Share

  36. ZEMLOK SK, Woodard E, Yu J
    Contact Allergens in Topical Therapies Commonly used in Eczema and Seborrheic Dermatitis: A reference guide for prescribing clinicians.
    J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02923.
    >> Share

  37. LEE S, LeBovidge J, Berbert L, Barbieri JS, et al
    Validation of the Atopic Dermatitis Control Tool in Pediatric Patients with Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Oct 4:S0190-9622(25)02925.
    >> Share

  38. HSIEH TS, Lee HY, Abe R, Takei S, et al
    Development and validation of prognostic models using novel inflammatory markers for drug reactions with eosinophilia and systemic symptoms: An international multicenter cohort study.
    J Am Acad Dermatol. 2025;93:1027-1034.
    >> Share

  39. JOLY-CHEVRIER M, Alamari A, Muha J, Lachance Y, et al
    AI Chatbots for Atopic Dermatitis: Accuracy, Readability, and Concordance With AAD Guidelines.
    J Am Acad Dermatol. 2025 Oct 1:S0190-9622(25)02913.
    >> Share

    September 2025
  40. ISLAM RK, Islam KN, Haas CJ
    Response to Ting et al., "Atopic Dermatitis and Diabetes Risk: Additional Concerns.".
    J Am Acad Dermatol. 2025 Sep 29:S0190-9622(25)02912.
    >> Share

  41. TING CT, Chen BS, Wei JC
    Atopic Dermatitis and Diabetes Risk: Additional Concerns.
    J Am Acad Dermatol. 2025 Sep 29:S0190-9622(25)02911.
    >> Share

  42. BURKE SM, Beveridge M, Hatipoglu B, Murphy J, et al
    Association of GLP-1 Agonist Use with Atopic Dermatitis in Obese Patients: A Retrospective Cohort Study.
    J Am Acad Dermatol. 2025 Sep 29:S0190-9622(25)02903.
    >> Share

  43. ZHOU MH, Gold JAW, Hay RJ, Lipner SR, et al
    Association between atopic dermatitis and dermatophytosis: a TriNetX retrospective cohort study.
    J Am Acad Dermatol. 2025 Sep 26:S0190-9622(25)02896.
    >> Share

  44. HE H, Yu L, Yu B, Xu Z, et al
    Mapping the time-course and associated factors of placebo response to systemic immunomodulatory treatments for atopic dermatitis.
    J Am Acad Dermatol. 2025 Sep 23:S0190-9622(25)02879.
    >> Share

  45. NOEL WC 2ND, Shah A, Bercovitch L, Garza-Mayers AC, et al
    Health Insurance Coverage of Topical Medications in Vitiligo and Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Sep 19:S0190-9622(25)02864.
    >> Share

  46. HAGINO T, Uchiyama A, Kosaka K, Araki T, et al
    A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: Systemic therapy-naive versus -experienced patients.
    J Am Acad Dermatol. 2025 Sep 15:S0190-9622(25)02822.
    >> Share

  47. LU J, Wang Y, Zhou C, Deng L, et al
    Increased Cancer Risk and Mortality in Individuals with Atopic Dermatitis: Evidence from the NHANES.
    J Am Acad Dermatol. 2025 Sep 1:S0190-9622(25)02726.
    >> Share

    August 2025
  48. CHANG JW, Wang F
    Response to Wang et al., "Comments on 'Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis'".
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02699.
    >> Share

  49. BISSONNETTE R, Goleva E, Berdyshev E, Leung DYM, et al
    In response to: "Response to Bissonnette et al. Dupilumab treatment restores lesional and non-lesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy.
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02705.
    >> Share

  50. CLABBERS J, Boesjes C, van Geel M, de Bruin-Weller M, et al
    Response to Bissonnette et al. 'Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, p
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02703.
    >> Share

  51. WANG Y, Liu Z
    Comments on "Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis".
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02698.
    >> Share

  52. SHIVE M, Hawryluk E, Drucker AM, Frazer-Green L, et al
    Response to Chu et al's "Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based r
    J Am Acad Dermatol. 2025 Aug 27:S0190-9622(25)02552.
    >> Share

  53. BRUSTAD N, Wang T, Chen L, Kaiser H, et al
    Effect of prenatal high-dose vitamin D on childhood atopic dermatitis is modified by maternal cotinine metabolome: A secondary analysis of a randomized clinical trial.
    J Am Acad Dermatol. 2025 Aug 25:S0190-9622(25)02670.
    >> Share

  54. CHEN TL, Ma SH, Ou WF, Chen CC, et al
    Decreased Risk of Reduced Linear Growth Among Children with Atopic Dermatitis Receiving Dupilumab: A Cohort Study.
    J Am Acad Dermatol. 2025 Aug 18:S0190-9622(25)02646.
    >> Share

  55. BRAUN N, Lin C, Baker N, Peacker BL, et al
    Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes.
    J Am Acad Dermatol. 2025 Aug 18:S0190-9622(25)02645.
    >> Share

  56. BENANDI K, Spires A, Hansen A, Linfante A, et al
    Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network.
    J Am Acad Dermatol. 2025 Aug 12:S0190-9622(25)02388.
    >> Share

  57. CHANG JW, Wang F
    Response to Goleva et al., "Response to Chang et al's 'Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis'".
    J Am Acad Dermatol. 2025 Aug 7:S0190-9622(25)02558.
    >> Share

  58. GOLEVA E, Berdyshev E, Kreimer S, Leung DYM, et al
    Response to Chang et al's "Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis".
    J Am Acad Dermatol. 2025 Aug 6:S0190-9622(25)02557.
    >> Share

  59. GROLEAU AS, Mereniuk A, Makhzoum JP
    Current therapeutic options for adult patients with urticarial vasculitis: A scoping review.
    J Am Acad Dermatol. 2025;93:423-428.
    >> Share

    July 2025
  60. HAGINO T, Saeki H, Fujimoto E, Kanda N, et al
    Effectiveness of Tralokinumab for Upadacitinib-Refractory Atopic Dermatitis: 48-week Retrospective Study.
    J Am Acad Dermatol. 2025 Jul 19:S0190-9622(25)02528.
    >> Share

  61. XIONG G, Gupta S, Rao V, Abu-Hilal M, et al
    Topical Ruxolitinib is More Effective at Itch Reduction than Topical Roflumilast in Atopic Dermatitis: A Comparative Meta-Analysis.
    J Am Acad Dermatol. 2025 Jul 3:S0190-9622(25)02402.
    >> Share

    June 2025
  62. WEBER B, Karels S, Shaik J, Neeley A, et al
    Formaldehyde Allergic Contact Dermatitis: Evaluation of Paper-Based Menstrual Products as a Potential Route of Exposure.
    J Am Acad Dermatol. 2025 Jun 25:S0190-9622(25)02387.
    >> Share

  63. SUN C, Zhang X, Su Z, Yao WH, et al
    Global, regional and national burdens of atopic dermatitis from 1990 to 2021: a trend analysis from the Global Burden of Disease Study 2021.
    J Am Acad Dermatol. 2025 Jun 19:S0190-9622(25)02369.
    >> Share

  64. DAVIS DMR, Frazer-Green L, Alikhan A, Bercovitch L, et al
    Focused update: Guidelines of care for the management of atopic dermatitis in adults.
    J Am Acad Dermatol. 2025 Jun 17:S0190-9622(25)02125.
    >> Share

  65. MANN C, Wollenberg A, Stander S, Staubach P, et al
    Risk of developing sleep disorders and psychologic comorbidity in children with inflammatory skin diseases-A population-based study.
    J Am Acad Dermatol. 2025;92:1261-1268.
    >> Share

    May 2025
  66. PALLER AS, Siegfried EC, Cork MJ, Kabashima K, et al
    Efficacy and safety of dupilumab in pediatric patients aged 6 months to 11 years with erythrodermic atopic dermatitis: A post-hoc analysis of three clinical trials.
    J Am Acad Dermatol. 2025 May 27:S0190-9622(25)02204.
    >> Share

  67. RIGALI S, Liszewski W
    Allergens in hair relaxer products: a potential source of allergic contact dermatitis in patients with textured hair.
    J Am Acad Dermatol. 2025 May 22:S0190-9622(25)02191.
    >> Share

  68. BISSONNETTE R, Gold LS, Kircik L, Simpson EL, et al
    Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis.
    J Am Acad Dermatol. 2025 May 16:S0190-9622(25)02130.
    >> Share

  69. EICHENFIELD LF, Stein Gold LF, Simpson EL, Zaenglein AL, et al
    Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study.
    J Am Acad Dermatol. 2025 May 14:S0190-9622(25)02124.
    >> Share

  70. KARELS S, Weber B, Ophaug S, Lee K, et al
    Evaluation of Nickel Content in Commercial Razors: Implications for Dermatologic Management of Nickel Allergy.
    J Am Acad Dermatol. 2025 May 10:S0190-9622(25)02107.
    >> Share

  71. ISLAM RK, Magharehabed Y, Islam KN, Joseph JM, et al
    Increased risk of type 2 diabetes in patients with atopic dermatitis: An age-stratified analysis using TriNetX.
    J Am Acad Dermatol. 2025 May 7:S0190-9622(25)00709.
    >> Share

  72. KALTCHENKO M, Radtke S, Kim E, Wan J, et al
    Response to Lai and Wei's "Comment on Kaltchenko et al.'s 'Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: A real-world cohort analysis.".
    J Am Acad Dermatol. 2025 May 5:S0190-9622(25)00692.
    >> Share

  73. LAI IC, Wei JC
    Comment on Kaltchenko et al.'s "Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: A real-world cohort analysis.".
    J Am Acad Dermatol. 2025 May 4:S0190-9622(25)00691.
    >> Share

    April 2025
  74. JOSHI A, Gawey L, Rahman M, Ghanshani R, et al
    Post-Marketing Safety Analysis of Upadacitinib in Atopic Dermatitis: An FDA Adverse Reporting System (FAERS) Review of Boxed Warning Related Adverse Events.
    J Am Acad Dermatol. 2025 Apr 25:S0190-9622(25)00681.
    >> Share

  75. CHANG JW, Huang X, Jiang W, Lun L, et al
    Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis.
    J Am Acad Dermatol. 2025 Apr 15:S0190-9622(25)00621.
    >> Share

  76. JIN Y
    Considerations on the Potential Link Between Dupilumab and Cutaneous T-cell Lymphoma in Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Apr 4:S0190-9622(25)00563.
    >> Share

  77. NICHOLAS A, Fleischer AB Jr
    Race and appointment availability influence continuity of care for chronic inflammatory skin disease: A cross-sectional study of United States practice data.
    J Am Acad Dermatol. 2025;92:753-760.
    >> Share

  78. LI R, Zhang J, Wang L, Zhang LY, et al
    Comments on "Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: a real-world cohort analysis".
    J Am Acad Dermatol. 2025 Apr 1:S0190-9622(25)00554.
    >> Share

  79. KALTCHENKO M, Kim E, Radtke S, Wan J, et al
    Response to Li et al.'s "Comments on 'Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: A real-world cohort analysis".
    J Am Acad Dermatol. 2025 Apr 1:S0190-9622(25)00555.
    >> Share

    March 2025
  80. KANTOR J
    This Month in JAAD International: June 2025: Atopic dermatitis, puberty, and the benefits of nationwide cohort studies.
    J Am Acad Dermatol. 2025 Mar 29:S0190-9622(25)00551.
    >> Share

  81. HERMAN KE, Beck LA, Jarvinen KM
    Updates to the role of diet in atopic dermatitis.
    J Am Acad Dermatol. 2025 Mar 29:S0190-9622(25)00550.
    >> Share

  82. YOUN CG, Pour Mohammad A, Marqueling AL, Siegel DH, et al
    Association Between Supplemental Nutrition Assistance Program (SNAP) and Cost-Related Medical Care Delays in Pediatric Atopic Dermatitis: A Cross-Sectional Analysis of the National Health Interview Survey, 1999-2018.
    J Am Acad Dermatol. 2025 Mar 15:S0190-9622(25)00446.
    >> Share

  83. GUPTA S, Xiong G, Shenouda C, Keow S, et al
    Ruxolitinib versus Roflumilast: A Meta-analysis of the Comparative Efficacy of Two Topical Therapies for Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Mar 14:S0190-9622(25)00438.
    >> Share

    February 2025
  84. DAHABREH D, Lo JC, Chandra M, Chiou AS, et al
    Atopic Dermatitis Prevalence among Asian American and Pacific Islander Children: A Retrospective Study in a Northern California Healthcare System.
    J Am Acad Dermatol. 2025 Feb 9:S0190-9622(25)00256.
    >> Share

  85. LIAO V, Lavin L, Pulitzer MP, Stuver R, et al
    Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: A retrospective cohort study from a single tertiary cancer center.
    J Am Acad Dermatol. 2025 Feb 1:S0190-9622(25)00188.
    >> Share

  86. RAU A, Leahr G, Del Pozo D, Hoffstad O, et al
    Atopic Dermatitis: Association of maternal and child history of celiac disease and the child's development of atopic dermatitis.
    J Am Acad Dermatol. 2025 Feb 1:S0190-9622(25)00178.
    >> Share

    January 2025
  87. LI Z, Xiao Y, Chen X, Gu X, et al
    Temporal Trends in the Prevalence and Burden of Atopic Dermatitis Worldwide from 1990 to 2021.
    J Am Acad Dermatol. 2025 Jan 31:S0190-9622(25)00163.
    >> Share

  88. SANDLER M, Kim EJ, Chen LC, Yu J, et al
    Discrepancies in Patch Testing Timing and Outcomes: A Retrospective Analysis of the Pediatric Allergic Contact Dermatitis Registry.
    J Am Acad Dermatol. 2025 Jan 31:S0190-9622(25)00165.
    >> Share

  89. HAGINO T, Saeki H, Fujimoto E, Kanda N, et al
    A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus -experienced patients.
    J Am Acad Dermatol. 2025 Jan 27:S0190-9622(25)00132.
    >> Share

  90. SOOD S, Wiseman M, Bagit A, Maliyar K, et al
    Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective study.
    J Am Acad Dermatol. 2025 Jan 24:S0190-9622(25)00131.
    >> Share

  91. BISSONNETTE R, Goleva E, Berdyshev E, Garcia S, et al
    Dupilumab treatment restores lesional and non-lesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD
    J Am Acad Dermatol. 2025 Jan 22:S0190-9622(25)00113.
    >> Share

  92. RODRIGUEZ R, Szeto MD, Hydol-Smith J, Burnette C, et al
    Higher Odds of Dupilumab Prescriptions for Black Patients with Atopic Dermatitis: Results of a Retrospective Study Using DataDerm, The Database of The American Academy of Dermatology.
    J Am Acad Dermatol. 2025 Jan 21:S0190-9622(25)00105.
    >> Share

  93. KALTCHENKO M, Radtke S, Kim E, Wan J, et al
    Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: a real-world cohort analysis.
    J Am Acad Dermatol. 2025 Jan 18:S0190-9622(25)00104.
    >> Share

  94. PHAN S, Hajek A, Rangel SM, Ren Z, et al
    Stigma Underlies the Mental Health Burden of Pediatric Atopic Dermatitis: A Cohort Study.
    J Am Acad Dermatol. 2025 Jan 3:S0190-9622(25)00004.
    >> Share

    December 2024
  95. GUTTMAN-YASSKY E, Rosmarin D, de Bruin-Weller M, Weidinger S, et al
    The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials.
    J Am Acad Dermatol. 2024 Dec 27:S0190-9622(24)03414.
    >> Share

  96. WU PA, Wu J, Liu R, Sullivan S, et al
    Epidermal spongiotic Langerhans cell collections, but not eosinophils, are a clue to the diagnosis of allergic contact dermatitis: A series of 170 clinically- and patch test-confirmed cases.
    J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03379.
    >> Share

    November 2024
  97. BRODELL RT
    JAAD Game Changers: "Diet in dermatology: Part I. Atopic dermatitis, acne, and nonmelanoma skin cancer".
    J Am Acad Dermatol. 2024 Nov 28:S0190-9622(24)03276.
    >> Share

  98. CHOI UE, Deng J, Parthasarathy V, Liao V, et al
    Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis.
    J Am Acad Dermatol. 2024 Nov 28:S0190-9622(24)03273.
    >> Share

  99. MASISON J, Beltrami EJ, Gronbeck C, Feng H, et al
    Differential patient travel burden to pediatric atopic dermatitis clinical trial sites.
    J Am Acad Dermatol. 2024 Nov 8:S0190-9622(24)03109.
    >> Share

    October 2024
  100. SINGAL A, Lipner HI, Neubauer Z, Lipner SR, et al
    Higher Sodium Excretion Is Not Associated With Increased Odds of Developing Atopic Dermatitis in a Large Retrospective Cohort Study.
    J Am Acad Dermatol. 2024 Oct 21:S0190-9622(24)03032.
    >> Share

  101. PALLER AS, de Bruin-Weller M, Marcoux D, Baselga E, et al
    Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDISTAD.
    J Am Acad Dermatol. 2024 Oct 8:S0190-9622(24)02919.
    >> Share

  102. ELGHAZZAWY MB, Nassir S, Arora JS, Min MS, et al
    A retrospective cohort study investigating cutaneous vasculitis in the setting of COVID-19 notes higher rates of IgA vasculitis.
    J Am Acad Dermatol. 2024;91:757-759.
    >> Share

  103. OBIJIOFOR CE, Sikora M, Liu L, Stern MJ, et al
    Investigating corrected QT prolongation with hydroxychloroquine use among patients with cutaneous sarcoidosis: A multicenter retrospective study.
    J Am Acad Dermatol. 2024;91:740-742.
    >> Share

    September 2024
  104. NGUYEN TV, Marcus AF, Sinnott SJ, Coleman A, et al
    Commentary: Response to "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study".
    J Am Acad Dermatol. 2024 Sep 30:S0190-9622(24)02901.
    >> Share

  105. PALLER AS, Silverberg JI, Simpson EL, Cork MJ, et al
    The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study.
    J Am Acad Dermatol. 2024 Sep 28:S0190-9622(24)02896.
    >> Share

  106. GUILLEMIN C, Bellon N, Jachiet M, Barbarot S, et al
    Dupilumab in atopic-dermatitis-like eczema associated with inborn errors of immunity: a nationwide study.
    J Am Acad Dermatol. 2024 Sep 27:S0190-9622(24)02885.
    >> Share

  107. NEUBAUER ZJK, Brunner PM, Geskin LJ, Guttman E, et al
    Decoupling the Association of Dupilumab with Cutaneous T-Cell Lymphoma Reply to "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study.".
    J Am Acad Dermatol. 2024 Sep 7:S0190-9622(24)02812.
    >> Share

  108. MATEI I, Bettuzzi T, Peiffer B, Ingen-Housz-Oro S, et al
    Evolution of the spectrum of drugs associated with acute generalized exanthematous pustulosis over time: A pharmacovigilance study.
    J Am Acad Dermatol. 2024;91:555-557.
    >> Share

  109. INGEN-HOUSZ-ORO S, Guichard E, Milpied B, Bensaid B, et al
    Topical versus oral corticosteroids in moderate drug reaction with eosinophilia and systemic symptoms: A multicenter randomized clinical trial.
    J Am Acad Dermatol. 2024;91:544-547.
    >> Share

    August 2024
  110. MA EZ, Bao A, Ahmadi M, Zhang J, et al
    Dupilumab is associated with reduced risk of acute upper respiratory infections in atopic dermatitis patients compared to non-targeted immunosuppressants: a multi-center cohort study.
    J Am Acad Dermatol. 2024 Aug 30:S0190-9622(24)02756.
    >> Share

  111. HASAN I, Zinn Z
    Response to Flynn et al. "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Aug 27:S0190-9622(24)02727.
    >> Share

  112. CHO YT, Chu CY
    Comments on "dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T-cell lymphoma: a retrospective cohort study".
    J Am Acad Dermatol. 2024 Aug 24:S0190-9622(24)02739.
    >> Share

  113. FLYNN E, Leonard N, Svoboda R
    Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Aug 23:S0190-9622(24)02726.
    >> Share

  114. CHAIYABUTR C, Dawe R, Lesar A, Ibbotson SH, et al
    Continuum of Light Sensitivity in Atopic Dermatitis: A Retrospective Analysis of 139 Cases in Scotland.
    J Am Acad Dermatol. 2024 Aug 22:S0190-9622(24)02710.
    >> Share

  115. SEE TOW HX, Yeok-Loo Lim A, Ci-En Choi E
    Response to: Bocquel et al., "Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study".
    J Am Acad Dermatol. 2024 Aug 21:S0190-9622(24)02661.
    >> Share

  116. GEORGE SE, Yu J
    Tralokinumab as an Effective Alternative after Dupilumab Treatment Failure in Moderate-to-Severe Atopic Dermatitis: A Real-World Study.
    J Am Acad Dermatol. 2024 Aug 20:S0190-9622(24)02700.
    >> Share

  117. RIVA HR, Woodruff CM
    Allergens and consumer warnings in at-home acrylic manicure kits.
    J Am Acad Dermatol. 2024 Aug 13:S0190-9622(24)02655.
    >> Share

  118. KRIDIN K, Ludwig RJ
    Reply to: "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study".
    J Am Acad Dermatol. 2024 Aug 6:S0190-9622(24)02574.
    >> Share

  119. CHEN TL, Ma SH
    Comments on the risk of cutaneous T cell lymphoma among patients with atopic dermatitis receiving dupilumab.
    J Am Acad Dermatol. 2024 Aug 6:S0190-9622(24)02573.
    >> Share

  120. HEYMANN WR
    Dupilumab's duplicity.
    J Am Acad Dermatol. 2024;91:249-250.
    >> Share

  121. SAMARAKOON U, Wolfson AR, Zhou L, Bassir F, et al
    Understanding the patient experience of drug reaction with eosinophilia and systemic symptoms: A qualitative study.
    J Am Acad Dermatol. 2024;91:370-373.
    >> Share

  122. GEORGE SE, Yu J
    Patch testing outcomes in children at the Massachusetts General Hospital.
    J Am Acad Dermatol. 2024;91:354-356.
    >> Share

    July 2024
  123. ZIEBART RL, Haberecht H, Davis MD, Wetter DA, et al
    Vancomycin-Associated Drug induced Hypersensitivity Syndrome: A Retrospective Cohort Study.
    J Am Acad Dermatol. 2024 Jul 29:S0190-9622(24)02556.
    >> Share

  124. PEZZOLO E, Narcisi A, Gargiulo L, Di Lernia V, et al
    Successful response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: a multicenter case series study.
    J Am Acad Dermatol. 2024 Jul 22:S0190-9622(24)02538.
    >> Share

  125. ZHAO Y, Zhang L, Zhang J
    Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
    J Am Acad Dermatol. 2024 Jul 20:S0190-9622(24)02498.
    >> Share

  126. WU KJ, Wei KC
    Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Jul 19:S0190-9622(24)02496.
    >> Share

  127. MEROLA JF, Chiou AS, During E, Foley P, et al
    Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study.
    J Am Acad Dermatol. 2024 Jul 13:S0190-9622(24)02483.
    >> Share

  128. SHIH PC, Wei JCC
    Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Jul 11:S0190-9622(24)01041.
    >> Share

  129. HASAN I, Zinn Z
    Response to Shih et al. "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Jul 10:S0190-9622(24)01046.
    >> Share

  130. MCKENZIE NC, Buras MR, Yiannias JA, Hall MR, et al
    Cost-effectiveness of patch testing allergens within the same group - a computational approach to optimize formaldehyde-related allergen selection.
    J Am Acad Dermatol. 2024 Jul 5:S0190-9622(24)01000.
    >> Share

  131. BAO A, Su HJ, Wan J
    Comparative Safety Analysis of Anti-IL-4/IL-13 Inhibitors and JAK Inhibitors in Atopic Dermatitis.
    J Am Acad Dermatol. 2024 Jul 4:S0190-9622(24)01003.
    >> Share

  132. BRODELL RT
    JAAD Game Changer: Etanercept therapy for toxic epidermal necrolysis.
    J Am Acad Dermatol. 2024;91:191.
    >> Share

    June 2024
  133. GRANT-KELS JM
    JAAD Game Changers: "Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate".
    J Am Acad Dermatol. 2024 Jun 13:S0190-9622(24)00901.
    >> Share

  134. LIN TL, Fan YH, Fan KS, Juan CK, et al
    Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study.
    J Am Acad Dermatol. 2024 Jun 13:S0190-9622(24)00788.
    >> Share

  135. KEOW S, Abu-Hilal M
    Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study.
    J Am Acad Dermatol. 2024 Jun 8:S0190-9622(24)00891.
    >> Share

  136. GANTZ HY, Greenzaid JD, Feldman SR
    Atopic dermatitis may not confer clinically meaningful risk of inflammatory bowel disease or renal malignancy.
    J Am Acad Dermatol. 2024 Jun 4:S0190-9622(24)00841.
    >> Share

  137. YAMANAKA-TAKAICHI M, Watanabe M, Comfere NI, Sokumbi O, et al
    Differentiating generalized pustular psoriasis from acute generalized exanthematous pustulosis.
    J Am Acad Dermatol. 2024;90:1289-1291.
    >> Share

  138. CURTIS KK, Dillan MM, Sharma TR, Piktel J, et al
    COVID-19 infection increases the development of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort analysis.
    J Am Acad Dermatol. 2024;90:1300-1302.
    >> Share

  139. WANG S, Laageide L, Phan V, Rosenbach M, et al
    Use of registry surveys in cutaneous sarcoidosis.
    J Am Acad Dermatol. 2024;90:1294-1296.
    >> Share

  140. SIMPSON EL, Silverberg JI, Worm M, Honari G, et al
    Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
    J Am Acad Dermatol. 2024;90:1190-1199.
    >> Share

  141. PATTERSON A
    JAAD Game Changer: Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study.
    J Am Acad Dermatol. 2024;90:1318.
    >> Share

  142. ELSTON DM
    Letter from the Editor: Drug reaction with eosinophilia and systemic symptoms syndrome.
    J Am Acad Dermatol. 2024;90:1153-1154.
    >> Share

  143. BLUMENTHAL KG, Alvarez-Arango S, Kroshinsky D, Lo YC, et al
    Drug reaction eosinophilia and systemic symptoms: Clinical phenotypic patterns according to causative drug.
    J Am Acad Dermatol. 2024;90:1240-1242.
    >> Share

    May 2024
  144. RIGALI S, Cozzi C, Liszewski W
    Identification of the Pigments Used in Permanent Makeup and Their Ability to Elicit Allergic Contact Dermatitis.
    J Am Acad Dermatol. 2024 May 31:S0190-9622(24)00830.
    >> Share

  145. WOHLTMANN WE
    JAAD Game Changers: "Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study".
    J Am Acad Dermatol. 2024 May 30:S0190-9622(24)00824.
    >> Share

  146. UBUKATA N, Hashizume H, Nakatani E, Sasaki H, et al
    Risk Factors and Drugs Associated with the Development of Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Population-Based Cohort Study Using the Shizuoka Kokuho Database.
    J Am Acad Dermatol. 2024 May 23:S0190-9622(24)00816.
    >> Share

  147. SILVERBERG JI, Eichenfield LF, Hebert AA, Simpson EL, et al
    Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials.
    J Am Acad Dermatol. 2024 May 20:S0190-9622(24)00755.
    >> Share

  148. ELSTON DM
    This month in JAAD: May 2024.
    J Am Acad Dermatol. 2024;90:930.
    >> Share

  149. SILVERBERG JI, Kirsner RS, Margolis DJ, Tharp M, et al
    Efficacy and safety of crisaborole ointment, 2%, in participants aged >/=45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
    J Am Acad Dermatol. 2024;90:945-952.
    >> Share

  150. ZHANG L, Li X, Xu X, Le Y, et al
    Ixekizumab-induced urticaria is associated with the short duration of remission in psoriasis by activation of mast cells.
    J Am Acad Dermatol. 2024;90:970-976.
    >> Share

  151. SAKUNCHOTPANIT G, Rohan TZ, Milosavljevic S, Patil MK, et al
    Procalcitonin: A potentially useful serum test in patients with dermatologic disease.
    J Am Acad Dermatol. 2024;90:1090-1091.
    >> Share

  152. WOHLTMANN WE
    JAAD Game Changer: Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients.
    J Am Acad Dermatol. 2024;90:1114.
    >> Share

    April 2024
  153. ZHANG J, Boesjes CM, Loman L, Kamphuis E, et al
    Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry.
    J Am Acad Dermatol. 2024 Apr 21:S0190-9622(24)00641.
    >> Share

  154. LEIBOWITZ R, Fischer A, Collins LF, Feldman RJ, et al
    HIV-related exclusion criteria in atopic dermatitis and prurigo nodularis clinical trials.
    J Am Acad Dermatol. 2024 Apr 12:S0190-9622(24)00633.
    >> Share

  155. HASAN I, Parsons L, Duran S, Zinn Z, et al
    Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.
    J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566.
    >> Share

  156. POWERS CM, Piontkowski AJ, Orloff J, Pulsinelli J, et al
    Risk of lymphoma in patients with atopic dermatitis: A case-control study in the All of Us database.
    J Am Acad Dermatol. 2024 Apr 4:S0190-9622(24)00554.
    >> Share

    March 2024
  157. MANZAR D, Suntres E, Nair N, Patel Y, et al
    Elevation of Creatine Phosphokinase in Moderate-Severe Atopic Dermatitis is Associated with the use of JAK inhibitors but not Dupilumab: A Systematic Review and Meta-Analysis.
    J Am Acad Dermatol. 2024 Mar 28:S0190-9622(24)00538.
    >> Share

  158. HREN MG, Guenin S, Khattri S
    Successful use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease.
    J Am Acad Dermatol. 2024 Mar 15:S0190-9622(24)00492.
    >> Share

    November 2023
  159. JOHNSON H, Aquino MR, Snyder A, Collis RW, et al
    Prevalence of allergic contact dermatitis in children with and without atopic dermatitis: A multicenter retrospective case-control study.
    J Am Acad Dermatol. 2023;89:1007-1014.
    >> Share

    October 2023
  160. RONNSTAD ATM, Thomsen SF, Thyssen JP, Egeberg A, et al
    The burden of head-and-neck dermatitis in adults with atopic dermatitis and its association with asthma, rhinitis, and disease severity.
    J Am Acad Dermatol. 2023 Oct 28:S0190-9622(23)03046.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016